Provided by Tiger Trade Technology Pte. Ltd.

ALPHAMAB-B

8.965
0.000
Volume:- -
Turnover:- -
Market Cap:8.68B
PE:-74.71
High:8.965
Open:8.965
Low:8.965
Close:8.965
52wk High:15.750
52wk Low:6.230
Shares:968.00M
HK Float Shares:968.00M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.120
ROE:-6.43%
ROA:-4.42%
PB:4.35
PE(LYR):-74.71
PS:13.13

Loading ...

Alphamab secures NMPA clearance for bispecific antibody Anbenitamab in second-line HER2-positive gastric cancer

Bulletin Express
·
May 29

ALPHAMAB-B (09966) Announces NMPA Approval for Ennituo® (Anituo Monoclonal Antibody Injection)

Stock News
·
May 29

Alphamab Oncology - Anbenitamab Injection (Kn026) Obtains Marketing Approval From Nmpa in China

THOMSON REUTERS
·
May 29

3D Medicines says Phase III data for Envafolimab plus GEMOX in advanced biliary tract cancer to be presented at 2026 ASCO meeting

Reuters
·
May 27

ALPHAMAB-B Shares Surge as Key Research Findings Selected for Prestigious 2026 ASCO Conference

Stock News
·
May 26

Assessing Alphamab Oncology’s Valuation After JSKN033 Phase II Trial Progress In Advanced Cervical Cancer

Simply Wall St.
·
May 26

ALPHAMAB-B Shares Surge Over 5% on Milestone Enrollment Completion for Envafolimab's New Indication Phase III Trial

Stock News
·
May 22

Alphamab Oncology Expands Share Capital by 0.009 % Through Option Exercise

Bulletin Express
·
May 21

ALPHAMAB-B Issues Shares Following Option Exercise

Stock News
·
May 21

Alphamab Oncology Outlines 12 June 2026 AGM Agenda, Seeks Fresh Share Issuance and Repurchase Mandates

Bulletin Express
·
May 20

Alphamab Oncology Sets 12 June 2026 AGM; Seeks 10% Buy-back and 20% Issuance Mandates, Plans Director Re-elections and Auditor Renewal

Bulletin Express
·
May 20

Alphamab Oncology announces annual general meeting

Reuters
·
May 20

Biotech Stocks Plunge Amid Global Bond Selloff and Rising Interest Rate Concerns

Stock News
·
May 18

Alphamab Oncology Doses First Patient in Phase 2 Study of JSKN033

MT Newswires Live
·
May 13

ALPHAMAB-B (09966) Announces First Patient Dosed in Phase II Study for JSKN033 in First-Line Advanced Cervical Cancer

Stock News
·
May 13

Alphamab Oncology doses first patient in Phase II JSKN033 cervical cancer trial

Reuters
·
May 13

HK Movers | Biotech Stocks Jump. InnoGen up over 44%; Clover Bio up over 11%; Junshi Bio up 9%; Laekna up 8%; Asymchem up over 3%; Tigermed up 2%

Tiger Newspress
·
May 11

Alphamab Oncology Maintains Steady Share Base in April 2026, Confirms Adequate Public Float

Bulletin Express
·
May 07

Alphamab Oncology Swings to Loss in 2025

MT Newswires Live
·
Apr 29

ALPHAMAB-B 2025年营收5.66亿元 研发投入攀升至5.72亿元致净亏1.14亿元

Bulletin Express
·
Apr 28